Drug General Information
Drug ID	D08DPN
Former ID	DIB009298
Drug Name	GSK-625433
Synonyms	NS5B HCV polymerase inhibitors, GlaxoSmithKline; SB-711845; SB-750330; 625433
Drug Type	Small molecular drug
Indication	HCV infection [ICD9: 070.4, 070.5, 070.70; ICD10:B17.1, B18.2]		Phase 1	[521970]
Company	GlaxoSmithKline plc
Structure		Download 2D MOL 3D MOL
Formula	C26H32N4O5S
Canonical SMILES	N1([C@@](C[C@@H]([C@@H]1c1sccn1)COC)(C(=O)O)Cn1nccc1)C(<br />=O)c1cc(c(cc1)C(C)(C)C)OC
PubChem Compound ID	11569786
Target and Pathway
Target(s)	Hepatitis C virus NS5B polymerase	Target Info	Inhibitor	[544077]
References
Ref 521970	ClinicalTrials.gov (NCT00439959) Monotherapy Versus Placebo Over 14 or 17 Days in Healthy and Hepatitis C Infected Adults. U.S. National Institutes of Health.
Ref 544077	Preclinical Characterization of PF-00868554, a Potent Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase . Antimicrob Agents Chemother. 2009 June; 53(6): 2544-2552.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.